November 15, 2021 11:29 AM EST
News Briefing

Cas­sa­va be­ing in­ves­ti­gat­ed by un­named 'gov­ern­ment agen­cies'; Rock­et Phar­ma gives up­dat­ed da­ta on Danon dis­ease

Paul Schloesser

Associate Editor

Josh Sullivan

Max Gelman

Senior Editor

Cas­sa­va Sci­ences likes to fight fire with fire, with CEO Re­mi Bar­bi­er call­ing a cit­i­zen pe­ti­tion to halt de­vel­op­ment on its lead drug a short …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Im­munol­o­gy biotech In­ma­gene to join Nas­daq through re­verse merg­er with what's left of Ike­na

A service from the Financial Times